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Abstract 
Background: Chemotherapy is important component in the management of breast cancer.  To achieved better 
chemotherapy response, a predictive marker is needed.  Various studies shows that DUSP4 expression correlates 
with chemotherapy response.   Objectives: Aims of this study is to know association between DUSP4 expression 
with anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer.  Methods: This is an 
observational study with longitudinal study method, DUSP4 expression is confirmed with 
Immunohistochemistry, chemotherapy response is calculated using RECIST criteria.  Results: Total sample of 
this study were 63 breast cancer patients.  This study shows that there is a tendency for better chemotherapy 
response in DUSP4 expression, although it is not statistically significant (p=0.073).  Stratification of DUSP4 
expression analysis based on intrinsic subtype, DUSP4 expression correlated with luminal B subtype (p=0.024), 
OR : 2.33 (1.106 - 4.492).   
------------------------------------------------------------------------ 
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DUSP4 expression on other subtypes were no significantly correlated, luminal A (p=0.245) and Her2 (p=0.612).  
Conclusion: Overall DUSP4 expression is less associated with chemotherapy response.  DUSP4 expression on 
subtype Luminal B has a significant association with chemotherapy response.  
Keywords: Breast Cancer; Chemotherapy; Clinical Response; DUSP4; Intrinsic subtype; Anthracycline. 
1. Introduction  
Breast cancer is the most frequent cancer in women in the world, incidence approximately 1,380,000 and 
mortality 458,400 cases every year [1].  Incidence in Indonesia estimated 48,998 breast cancer every year, most 
of them present in advanced stage [2, 3]. 
Neoadjuvant chemotherapy has become a standard in advanced stage breast cancer management [4].  
Neoadjuvant chemotherapy offers many advantages  [5]. Anthracycline-based chemotherapy is most often used 
in breast cancer chemotherapy [6].   
Anthracycline has long term accumulated toxicity: cardiac dysfunction, myelodysplasia and leukemia [6, 7].  
Anthracycline also has limitation in breast cancer related to drug resistancy [8, 9].  
Breast cancer patient with the same staging dan given with the same chemotherapy regiment doesn’t always has 
the same outcome. To achieved better clinical response, it is needs a predictive marker on breast cancer [10].  
An ideal biomarker should differ various response to certain chemotherapy agent, before a chemotherapy 
procedure has done [5, 11].  
Study on residual breast cancer sample patient after neoadjuvant chemotherapy, found polymorphisms of 
DUSP4 on residual tumor [12].  DUSP4 is an enzyme which inactivates kinase target through dephosphorylase 
phosphoserine residual and phosphotyrosine [13-15].  DUSP4 acts as ERK phosphatase. Inhibition of ERK 
phosphatase reduces tumor sensitivity to  chemotherapy.  
DUSP4 correlated negatively with MEK-ERK pathway.  DUSP4 expression can predict MEK-ERK activity.  
Chemotherapy will be more effective if DUSP4 is expressed [12, 16, 17]. 
Because of the importance of predictive marker in management of  breast cancer, we are interested to study the 
DUSP4 expression in breast cancer with chemotherapy response.  The objective of this study is to know the 
association between DUSP4 expression with Anthracycline-based chemotherapy response in locally advanced 
breast cancer patients.   
2. Materials and Method 
2.1. Collection of Samples 
This is an observational study with longitudinal study model.  Study was conducted within a population of 
breast cancer patients who had been diagnosed through clinical and histopathology examination, which entered 
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the Wahidin Sudiro Husodo Hospital in Makassar, South Sulawesi, Indonesia, starting from October 2014 to 
September 2015.   
Inclusion criteria are locally advanced breast cancer female patient, invasive ductal breast cancer, receiving 
neoadjuvant chemotherapy with CAF (Cyclophophamide, Adriamycine, 5-FU) regiment.  Exclusion criteria 
were inadequate tissue samples for immunohistochemistry and bilateral breast cancer.  
All samples who fulfilled inclusion and exclusion criteria and willing to participate in the study and signing 
informed consent recruited as study samples. Total samples of this study were 63 breast cancer patients.  
2.2. Expression DUSP4 by Immunohistochemistry 
DUSP4 expression is measured with immunohistochemistry as described by Hyunsung Kim and his colleagues 
2015.  DUSP4 expression is evaluated from its coloring intensity and size.   
Coloring intensity is scored : negative (0), weak (18), medium (2) and strong (3), and coloring size is scored: 
0% (0), 1-25% (18), 26-50% (2), 51-75% (3) and 76-100% (4). Final score  was results of Intensity times the 
coloring score.  DUSP4 expression is classified as negative (score 0-3) and positive (score 4-12). [19, 20]  
2.3. Classification of clinical response to chemotherapy 
Chemotherapy response is classified as nonresponsive, if tumor size is reduced ≤ 30%, no change or increased 
in tumor size, or if found a new tumor; while responsive, if tumor is disappear, or there is a reduction >30% and 
no new tumor found.  
2.4. Data Analysis 
Data analysis using the SPSS (Statistical Package for Social Science) version 22. Analysis of patient’s 
characteristics and clinical response using chi square.  
2.5. Ethical Clearence 
Ethical approval for this study was obtained from Research Ethics Committee, Faculty of Medicine, Hasanuddin 
University, Makassar, Indonesia. Number; 581/H4.8.4.5.31/PP36-KOMETIK/2015. 
3. Results 
In this study we have 63 breast cancer samples,  the youngest was 29 years old and the oldest one was 75 years 
old, the most age in population was the fourth decades 22/63 (35%).  Histopathologic we got Low Grade 9 cases 
(14.3%), Moderate Grade 33 cases (52.4%) dan High Grade  21 cases (33.3%).  
Immunohistochemistry panel we got Luminal A 14 (22.2%), Luminal B 26(41.3%), Her2 18 (28.6%) dan Triple 
Negative 5 (7.9%).  DUSP4 was expressed in 21/63 (33.3%).  Responsive to neoadjuvant chemotherapy CAF 
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regiment was 35/63 (55.6%).  Characteristic of samples can be see in the following table 1. 
Table 1: Clinicopathological characteristics 
Characteristic Number (Percentage %) 
AGE  
< 50 43 (68.3%) 
≥ 50 20  (31.7%) 
GRADE  
Low Grade 9 (14.3%) 
Moderate Grade 33 (52.4%) 
High Grade 21 (33.3%) 
SUBTYPE  
Luminal A 14 (22.2%) 
Luminal B 26 (41.3%) 
HER2 18 (28.6%) 
Triple Negative 5 (7.9%) 
DUSP4  
Positive 21 (33.3%) 
Negative 42 (61.7%) 
CLINICAL RESPONSE 
Responsive 35 (55.6%) 
Non-responsive 28 (44.4%) 
 
 
Figure 1: Microphotographs of Dual Specific Protein Phosphatase 4 (DUSP4) immunostaining in invasive 
ductal carcinoma.  Negative Results in 40 x and 400 x 
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Figure 2: Microphotographs of dual-specificity protein phosphatase 4 (DUSP4) immunostaining in invasive 
ductal carcinoma.  Positive results in 40 x and 400 x. The tumor cells showed cytoplasmic  DUSP4 staining. 
Table 2: Association between DUSP4 expression with clinical response to neoadjuvant Chemotherapy 
DUSP4 
Clinical Response 
Total p OR  (95%CI) 
Responsive Nonresponsive 
Positive 15 (71.4%) 6 (28.6%) 21(33.3%) 0,073 1.5  (0.98 –2.27) 
Negative  20 (47.6%) 22 (52.4%) 42(66.7%)   
 
DUSP4 expression has a tendency to affect chemotherapy response in breast cancer, it can be seen that positive 
DUSP4 tends to be responsive to neoadjuvant chemotherapy 15/21 (71.4%), and negative DUSP4 tends to be 
non-responsive to neoadjuvant chemotherapy 22/42 (52.4%).    
However, there is no significant difference statistically with p value = 0.073 (p>0.05.  It means that DUSP4 
expression is less associated with Anthracycline-based neoadjuvant chemotherapy 
Stratisfication of breast cancer based on intrinsic subtype, we got DUSP4 expression in Luminal A p value =  
0.24 ( > 0.05)    and in  Her2   p value =  0.61  ( > 0.05).  It means that DUSP4 expression in subtype Lumina A 
and Her2 are not associated with chemotherapy response in breast cancer.  
In subtype Luminal B, there are difference in clinical response between DUSP4 positive expression 10 (38.5 %) 
dan  DUSP4 negative expression 5 (19.2%), with p value = 0.021  (p<0.05).  
Value crude odds ratio (21) = 2.3   with confidence interval (95% CI) = (1.16 – 4.92).  It means that DUSP4 
expression in subtype Luminal B is associated with Anthracycline-based neoadjuvant chemotherapy.  
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Table 3: Correlation Between Subtype, DUSP4 with Chemotherapy Response 
SUBTYPE                     DUSP4 
CHEMOTHERAPY RESPONSE 
p OR (95%CI) 
Responsive 
n (%) 
Nonresponsive 
n (%) 
LUMINAL A DUSP4 Positive 3 (75) 1 (25) 0.245 2.5   (0.83 – 7.52) 
DUSP4 Negative 3 (30) 7 (70)  
LUMINAL B DUSP4 Positive 10 (83.3) 2 (16.7) 0.021 2.3   (1,16 – 4,92) 
DUSP4 Negative 5 (35.7) 9 (64.3)  
HER2 DUSP4 Positive 2 (40.0) 3 (60.0) 0.608 1.5   (0.57 – 4.20) 
DUSP4 Negative 8 (61.5) 5 (38.5)  
TRIPLE NEGATIVE DUSP4 Positive 0 (0) 0 (0)       
DUSP4 Negative 4 (80) 1 (20)  
 
4. Discussion 
Result of this study revealed that positive DUSP4 expression shows tendency for a better chemotherapy 
response compared to negative DUSP4 expression, but it is not statistically significant.  DUSP4 expression on 
Luminal B subtype is associated with chemotherapy response.   
Study on DUSP4 expression is still rare. Study on breast cancer profile shows expression of DUSP4 on 39/115 
(34%) sample, from DUSP4 which is expressed on protein level, 29 samples with gen amplification [22].  Other 
studies found that low DUSP4 expression is correlated to basal-like breast cancer, high tumor proliferation after 
chemotherapy, lack of response to chemotherapy and shortening of disease free survival.  In contrast,  over-
expression of DUSP4 is correlated to increasing apoptosis induced by chemotherapy [12, 16]. Other study found 
that low DUSP4 expression correlated to increasing recurency rate and mortality in triple negative breast cancer 
patients [23].  Study found that high DUSP4 expression needs a higher doxorubicin dosage, while cells with low 
DUSP4 expression need a lower doxorubicin dosage [8].  Study with other agent shows that DUSP4 also acts in 
regulating breast cancer cell sensitivity for other chemotherapy agents [8]. 
Study mentions that DUSP4 expression was significantly correlated with a larger tumor size (>2 cm, p=0.015). 
There was no significant correlation between overall survival or disease-free survival and DUSP4 expression in 
all 266 patients [19].   
The limitations of this study were; Neoadjuvant chemotherapy is only done three cycles, which aims to 
downsizing until the tumor becomes resectable, so that in this study no cases were found to achieve pCR 
(pathological complete response). Measurement of dependent variable were using the manual method by using a 
caliper, ideally using a measuring instrument such as CT SCAN / MRI. 
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5. Conclusion 
DUSP4 expression shows tendency of a better chemotherapy response, but it is not statistically significant.  
DUSP4 expression on Luminal B subtype has a significant correlation with chemotherapy response. 
Examination of DUSP4 Expression with immunohistochemically methods should be considered in patients with 
Breast Cancer mainly in Luminal B Subtypes undergoing chemotherapy, to obtain better treatment outcomes. 
Based on this study, it can be suggested for further study of DUSP4 expression in breast cancer. 
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